{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(23)"],"submitter":["Linhares Y"],"pubmed_abstract":["<h4>Abstract</h4>Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, 4-1BB chimeric antigen receptor (CAR) T-cell product approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). We present the OUTREACH primary analysis, evaluating the safety and efficacy of outpatient monitoring after liso-cel treatment at community sites in the United States. Adults with R/R LBCL after ≥2 prior lines of therapy received liso-cel. Outpatient vs inpatient monitoring was per investigator discretion. The primary end points were incidences of grade ≥3 cytokine release syndrome (CRS), neurological events (NEs), prolonged cytopenia, and infections. Efficacy was a secondary end point. Eighty-two patients received liso-cel (outpatient monitored, 70%; inpatient monitored, 30%). The med"],"journal":["Blood advances"],"pagination":["6114-6126"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11652776"],"repository":["biostudies-literature"],"pubmed_title":["OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL."],"pmcid":["PMC11652776"],"pubmed_authors":["Hoda D","Terebelo H","Bellomo C","Freytes CO","Maris M","Cherry M","Linhares Y","Varela JC","Sharman JP","Vedal M","Cross S","Espinola R","Avilion A","Courtright J","Yimer H","Ogasawara K","Essell J","Yuan B","Bachier C","Fanning S","Kostic A","Mattar B"],"additional_accession":[]},"is_claimable":false,"name":"OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL.","description":"<h4>Abstract</h4>Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, 4-1BB chimeric antigen receptor (CAR) T-cell product approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). We present the OUTREACH primary analysis, evaluating the safety and efficacy of outpatient monitoring after liso-cel treatment at community sites in the United States. Adults with R/R LBCL after ≥2 prior lines of therapy received liso-cel. Outpatient vs inpatient monitoring was per investigator discretion. The primary end points were incidences of grade ≥3 cytokine release syndrome (CRS), neurological events (NEs), prolonged cytopenia, and infections. Efficacy was a secondary end point. Eighty-two patients received liso-cel (outpatient monitored, 70%; inpatient monitored, 30%). The med","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Dec","modification":"2026-07-15T10:59:49.136Z","creation":"2025-04-04T00:38:52.916Z"},"accession":"S-EPMC11652776","cross_references":{"pubmed":["39347584"],"doi":["10.1182/bloodadvances.2024013254"]}}